Voyager Therapeutics (VYGR) Price to Sales (2015 - 2026)

Voyager Therapeutics has disclosed Price to Sales across 12 years of filings, most recently posting 67.02 for Q2 2026.

• In Q2 2026, Price to Sales rose 102.14% year-over-year to 67.02; the TTM figure through Jun 2026 stood at 6.21 (up 53.46% YoY), while the FY2025 annual figure was 5.75, up 48.17% from the prior year.
• Price to Sales came in at 67.02 for Q2 2026 at Voyager Therapeutics, down from 89.54 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 442.86 in Q1 2022 to a low of 151.96 in Q4 2022.
• Average Price to Sales over 5 years is 64.09, with a median of 27.31 recorded in 2024.
• The largest YoY upside for Price to Sales was 1527.6% in 2022 against a maximum downside of 4251.56% in 2022.
• Over 5 years, Price to Sales stood at 151.96 in 2022, then jumped by 102.72% to 4.13 in 2023, then soared by 1097.74% to 49.43 in 2024, then sank by 69.39% to 15.13 in 2025, then soared by 342.9% to 67.02 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 67.02 in Q2 2026, 89.54 in Q1 2026, and 15.13 in Q4 2025.